Postchemotherapy retroperitoneal lymph node dissection for testis cancer

References

• Einhorn LH. Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res.41(9 Pt 1), 3275–3280 (1981).
   PubMed Web of Science ®Google Scholar
• van Dijk MR, Steyerberg EW, Habbema JD. Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: an update based on meta-analysis. Eur. J. Cancer42(7), 820–826 (2006).
   PubMed Web of Science ®Google Scholar
• Fox EP, Weathers TD, Williams SD et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J. Clin. Oncol.11(7), 1294–1299 (1993).
   PubMed Web of Science ®Google Scholar
• Carver BS, Serio AM, Bajorin D et al. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. J. Clin. Oncol.25(35), 5603–5608 (2007).
   PubMedGoogle Scholar
• Flechon A, Tavernier E, Boyle H, Meeus P, Rivoire M, Droz JP. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour. BJU Int.106(6), 779–785 (2010).
   PubMed Web of Science ®Google Scholar
• Peterson M, Beck S, Bihrle R, Einhorn L, Foster R. Results of retroperitoneal lymph node dissection after chemotherapy in patients with pure seminoma in the orchidectomy specimen but elevated serum α-fetoprotein. BJU Int.104(2), 176–178 (2009).
   PubMedGoogle Scholar
• Mosharafa AA, Foster RS, Leibovich BC, Bihrle R, Johnson C, Donohue JP. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J. Urol.169(6), 2126–2128 (2003).
   PubMed Web of Science ®Google Scholar
• Puc HS, Heelan R, Mazumdar M et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan–Kettering Cancer Center. J. Clin. Oncol.14(2), 454–460 (1996).
   PubMed Web of Science ®Google Scholar
• Schultz SM, Einhorn LH, Conces DJ Jr, Williams SD, Loehrer PJ. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J. Clin. Oncol.7(10), 1497–1503 (1989).
   PubMed Web of Science ®Google Scholar
• Flechon A, Bompas E, Biron P, Droz JP. Management of post-chemotherapy residual masses in advanced seminoma. J. Urol.168(5), 1975–1979 (2002).
   PubMedGoogle Scholar
• De Santis M, Becherer A, Bokemeyer C et al. 2–18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J. Clin. Oncol.22(6), 1034–1039 (2004).
   PubMed Web of Science ®Google Scholar
• Lewis DA, Tann M, Kesler K, McCool A, Foster RS, Einhorn LH. Positron emission tomography scans in postchemotherapy seminoma patients with residual masses: a retrospective review from Indiana University Hospital. J. Clin. Oncol.24(34), e54–e55 (2006).
   PubMed Web of Science ®Google Scholar
• Johns Putra L, Lawrentschuk N, Ballok Z et al.18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy. Urology64(6), 1202–1207 (2004).
   PubMedGoogle Scholar
• Spermon JR, De Geus-Oei LF, Kiemeney LA, Witjes JA, Oyen WJ. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int.89(6), 549–556 (2002).
   PubMed Web of Science ®Google Scholar
• Hinz S, Schrader M, Kempkensteffen C et al. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J. Urol.179(3), 936–940; discussion 940 (2008).
   PubMedGoogle Scholar
• Fossa SD, Aass N, Ous S et al. Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer. J. Urol.142(5), 1239–1242 (1989).
   PubMed Web of Science ®Google Scholar
• Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med.316(23), 1435–1440 (1987).
   PubMed Web of Science ®Google Scholar
• Dearnaley DP, Horwich A, A’Hern R et al. Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up. Eur. J. Cancer27(6), 684–691 (1991).
   PubMedGoogle Scholar
• Horwich A, Stenning S. Initial chemotherapy for stage II testicular non-seminoma. World J. Urol.12(3), 148–150 (1994).
   PubMedGoogle Scholar
• Toner GC, Panicek DM, Heelan RT et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J. Clin. Oncol.8(10), 1683–1694 (1990).
   PubMedGoogle Scholar
• Carver BS, Bianco FJ Jr, Shayegan B et al. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. J. Urol.176(1), 100–103; discussion 103–104 (2006).
   PubMedGoogle Scholar
• Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J. Clin. Oncol.21(17), 3310–3317 (2003).
   PubMed Web of Science ®Google Scholar
• Steiner H, Peschel R, Bartsch G. Retroperitoneal lymph node dissection after chemotherapy for germ cell tumours: is a full bilateral template always necessary? BJU Int.102(3), 310–314 (2008).
   PubMedGoogle Scholar
• Debono DJ, Heilman DK, Einhorn LH, Donohue JP. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J. Clin. Oncol.15(4), 1455–1464 (1997).
   PubMed Web of Science ®Google Scholar
• Ehrlich Y, Brames MJ, Beck SD, Foster RS, Einhorn LH. Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J. Clin. Oncol.28(4), 531–536 (2010).
   PubMed Web of Science ®Google Scholar
• Donohue JP, Rowland RG, Kopecky K et al. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J. Urol.137(6), 1176–1179 (1987).
   PubMed Web of Science ®Google Scholar
• Beck SD, Foster RS, Bihrle R et al. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer. J. Urol.168(4 Pt 1), 1402–1404 (2002).
   PubMedGoogle Scholar
• Mosharafa AA, Foster RS, Leibovich BC et al. Histology in mixed germ cell tumors. Is there a favorite pairing? J. Urol.171(4), 1471–1473 (2004).
   PubMedGoogle Scholar
• Hendry WF, Norman AR, Dearnaley DP et al. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer94(6), 1668–1676 (2002).
   PubMed Web of Science ®Google Scholar
• Albers P, Weissbach L, Krege S et al. Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J. Urol.171(5), 1835–1838 (2004).
   PubMed Web of Science ®Google Scholar
• Steyerberg EW, Keizer HJ, Fossa SD et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariable analysis of individual patient data from six study groups. J. Clin. Oncol.13(5), 1177–1187 (1995).
   PubMed Web of Science ®Google Scholar
• Steyerberg EW, Gerl A, Fossa SD et al. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J. Clin. Oncol.16(1), 269–274 (1998).
   PubMed Web of Science ®Google Scholar
• Vergouwe Y, Steyerberg EW, Foster RS et al. Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patients. Eur. Urol.51(2), 424–432 (2007).
   PubMed Web of Science ®Google Scholar
• Vergouwe Y, Steyerberg EW, de Wit R et al. External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients. Br. J. Cancer88(6), 843–847 (2003).
   PubMed Web of Science ®Google Scholar
• Sanchez D, Zudaire JJ, Fernandez JM et al.18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse. BJU Int.89(9), 912–916 (2002).
   PubMed Web of Science ®Google Scholar
• Oechsle K, Hartmann M, Brenner W et al. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J. Clin. Oncol.26(36), 5930–5935 (2008).
   PubMed Web of Science ®Google Scholar
• Saxman SB, Nichols CR, Foster RS, Messemer JE, Donohue JP, Einhorn LH. The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers. J. Urol.155(2), 587–589 (1996).
   PubMed Web of Science ®Google Scholar
• Ong TA, Winkler MH, Savage PM, Seckl MJ, Christmas TJ. Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome. BJU Int.102(2), 198–202 (2008).
   PubMedGoogle Scholar
• Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J. Clin. Oncol.23(25), 6149–6156 (2005).
   PubMed Web of Science ®Google Scholar
• Albers P, Ganz A, Hannig E, Miersch WD, Muller SC. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J. Urol.164(2), 381–384 (2000).
   PubMed Web of Science ®Google Scholar
• Habuchi T, Kamoto T, Hara I et al. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers. Cancer98(8), 1635–1642 (2003).
   PubMed Web of Science ®Google Scholar
• Ravi R, Ong J, Oliver RT, Badenoch DF, Fowler CG, Hendry WF. Surgery as salvage therapy in chemotherapy-resistant nonseminomatous germ cell tumours. Br. J. Urol.81(6), 884–888 (1998).
   PubMedGoogle Scholar
• Coogan CL, Foster RS, Rowland RG et al. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. Urology50(6), 957–962 (1997).
   PubMed Web of Science ®Google Scholar
• Eastham JA, Wilson TG, Russell C, Ahlering TE, Skinner DG. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology43(1), 74–80 (1994).
   PubMed Web of Science ®Google Scholar
• Murphy BR, Breeden ES, Donohue JP et al. Surgical salvage of chemorefractory germ cell tumors. J. Clin. Oncol.11(2), 324–329 (1993).
   PubMed Web of Science ®Google Scholar
• Wood DP Jr, Herr HW, Heller G et al. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J. Urol.148(6), 1812–1815; discussion 1815–1816 (1992).
   PubMedGoogle Scholar
• Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP. Post chemotherapy RPLND in patients with elevated markers: current concepts and clinical outcome. Urol. Clin. North Am.34(2), 219–225 (2007).
   PubMed Web of Science ®Google Scholar
• Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. J. Urol.128(2), 315–320 (1982).
   PubMed Web of Science ®Google Scholar
• Weissbach L, Boedefeld EA. Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I. J. Urol.138(1), 77–82 (1987).
   PubMedGoogle Scholar
• Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965–1989. Br. J. Urol.71(3), 326–335 (1993).
   PubMedGoogle Scholar
• Donohue JP, Roth LM, Zachary JM, Rowland RG, Einhorn LH, Williams SG. Cytoreductive surgery for metastatic testis cancer: tissue analysis of retroperitoneal masses after chemotherapy. J. Urol.127(6), 1111–1114 (1982).
   PubMedGoogle Scholar
• Ehrlich Y, Yossepowitch O, Kedar D, Baniel J. Distribution of nodal metastases after chemotherapy in nonseminomatous testis cancer: a possible indication for limited dissection. BJU Int.97(6), 1221–1224 (2006).
   PubMed Web of Science ®Google Scholar
• Rabbani F, Goldenberg SL, Gleave ME, Paterson RF, Murray N, Sullivan LD. Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of residual masses sufficient? Br. J. Urol.81(2), 295–300 (1998).
   PubMedGoogle Scholar
• Carver BS, Shayegan B, Eggener S et al. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J. Clin. Oncol.25(28), 4365–4369 (2007).
   PubMedGoogle Scholar
• Beck SD, Foster RS, Bihrle R, Donohue JP, Einhorn LH. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? Cancer110(6), 1235–1240 (2007).
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Pfister D, Witthuhn R, Thuer D, Albers P. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur. Urol.55(1), 217–224 (2009).
   PubMed Web of Science ®Google Scholar
• Coogan CL, Hejase MJ, Wahle GR et al. Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J. Urol.156(5), 1656–1658 (1996).
   PubMedGoogle Scholar
• Nonomura N, Nishimura K, Takaha N et al. Nerve-sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy. Int J. Urol.9(10), 539–544 (2002).
   PubMedGoogle Scholar
• Miki T, Mizutani Y, Nakamura T et al. Post-chemotherapy nerve-sparing retroperitoneal lymph node dissection for advanced germ cell tumor. Int J. Urol.16(4), 379–382 (2009).
   PubMedGoogle Scholar
• Pettus JA, Carver BS, Masterson T, Stasi J, Sheinfeld J. Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. Urology73(2), 328–331; discussion 331–322 (2009).
   PubMed Web of Science ®Google Scholar
• Rukstalis DB, Chodak GW. Laparoscopic retroperitoneal lymph node dissection in a patient with stage 1 testicular carcinoma. J. Urol.148(6), 1907–1909; discussion 1909–1910 (1992).
   PubMed Web of Science ®Google Scholar
• Rassweiler JJ, Seemann O, Henkel TO, Stock C, Frede T, Alken P. Laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors: indications and limitations. J. Urol.156(3), 1108–1113 (1996).
   PubMed Web of Science ®Google Scholar
• Tobias-Machado M, Zambon JP, Ferreira AD et al. Retroperitoneal lymphadenectomy by videolaparoscopic transperitoneal approach in patients with non-seminomatous testicular tumor. Int. Braz. J. Urol.30(5), 389–396 (2004).
   PubMedGoogle Scholar
• Palese MA, Su LM, Kavoussi LR. Laparoscopic retroperitoneal lymph node dissection after chemotherapy. Urology60(1), 130–134 (2002).
   PubMed Web of Science ®Google Scholar
• Permpongkosol S, Lima GC, Warlick CA et al. Postchemotherapy laparoscopic retroperitoneal lymph node dissection: evaluation of complications. Urology69(2), 361–365 (2007).
   PubMedGoogle Scholar
• Steiner H, Zangerl F, Stohr B et al. Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer. J. Urol.180(4), 1348–1352 (2008).
   PubMedGoogle Scholar
• Maldonado-Valadez R, Schilling D, Anastasiadis AG, Sturm W, Stenzl A, Corvin S. Post-chemotherapy laparoscopic retroperitoneal lymph-node dissection in testis cancer patients. J. Endourol.21(12), 1501–1504 (2007).
   PubMed Web of Science ®Google Scholar
• Steiner H, Peschel R, Janetschek G et al. Long-term results of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience. Urology63(3), 550–555 (2004).
   PubMed Web of Science ®Google Scholar
• Albqami N, Janetschek G. Laparoscopic retroperitoneal lymph-node dissection in the management of clinical stage I and II testicular cancer. J. Endourol.19(6), 683–692; discussion 692 (2005).
   PubMed Web of Science ®Google Scholar
• Calestroupat JP, Sanchez-Salas R, Cathelineau X et al. Postchemotherapy laparoscopic retroperitoneal lymph node dissection in nonseminomatous germ-cell tumor. J. Endourol.23(4), 645–650 (2009).
   PubMed Web of Science ®Google Scholar
• Leibovitch I, Little JS Jr, Foster RS, Rowland RG, Bihrle R, Donohue JP. Delayed orchiectomy after chemotherapy for metastatic nonseminomatous germ cell tumors. J. Urol.155(3), 952–954 (1996).
   PubMedGoogle Scholar
• Ramani VA, Grey BR, Addla SK, Dunham MP, Sangar VK, Clarke NW. Histological outcome of delayed orchidectomy after primary chemotherapy for metastatic germ cell tumour of the testis. Clin. Oncol. (R. Coll. Radiol.)20(3), 247–252 (2008).
   PubMedGoogle Scholar
• Mosharafa AA, Foster RS, Koch MO, Bihrle R, Donohue JP. Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J. Urol.171(5), 1839–1841 (2004).
   PubMed Web of Science ®Google Scholar
• Nash PA, Leibovitch I, Foster RS, Bihrle R, Rowland RG, Donohue JP. En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer: indications, implications and outcomes. J. Urol.159(3), 707–710 (1998).
   PubMedGoogle Scholar
• Stephenson AJ, Tal R, Sheinfeld J. Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. J. Urol.176(5), 1996–1999 (2006).
   PubMedGoogle Scholar
• Beck SD, Lalka SG. Long-term results after inferior vena caval resection during retroperitoneal lymphadenectomy for metastatic germ cell cancer. J. Vasc. Surg.28(5), 808–814 (1998).
   PubMedGoogle Scholar
• Ehrlich Y, Kedar D, Zelikovski A, Konichezky M, Baniel J. Vena caval reconstruction during postchemotherapy retroperitoneal lymph node dissection for metastatic germ cell tumor. Urology73(2), 442.e17–e19 (2009).
   Google Scholar
• Beck SD, Foster RS, Bihrle R, Koch MO, Wahle GR, Donohue JP. Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection. J. Urol.165(5), 1517–1520 (2001).
   PubMed Web of Science ®Google Scholar
• Spitz A, Wilson TG, Kawachi MH, Ahlering TE, Skinner DG. Vena caval resection for bulky metastatic germ cell tumors: an 18-year experience. J. Urol.158(5), 1813–1818 (1997).
   PubMedGoogle Scholar
• Mullen JC, Lemermeyer G, Tittley J, Ameli FM, Lossing AG, Jewett MA. Metastatic testicular tumor requiring inferior vena cava resection. Urology47(2), 263–265 (1996).
   PubMedGoogle Scholar
• Kelly R, Skinner D, Yellin AE, Weaver FA. En bloc aortic resection for bulky metastatic germ cell tumors. J. Urol.153(6), 1849–1851 (1995).
   PubMedGoogle Scholar
• Tognoni PG, Foster RS, McGraw P et al. Combined post-chemotherapy retroperitoneal lymph node dissection and resection of chest tumor under the same anesthetic is appropriate based on morbidity and tumor pathology. J. Urol.159(6), 1833–1835 (1998).
   PubMedGoogle Scholar
• McGuire MS, Rabbani F, Mohseni H, Bains M, Motzer R, Sheinfeld J. The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminomatous germ cell tumours. BJU Int.91(6), 469–473 (2003).
   PubMedGoogle Scholar
• Steyerberg EW, Keizer HJ, Messemer JE et al. Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study Group. Cancer79(2), 345–355 (1997).
   PubMedGoogle Scholar
• Jacobsen NE, Beck SD, Jacobson LE, Bihrle R, Einhorn LH, Foster RS. Is retroperitoneal histology predictive of liver histology at concurrent post-chemotherapy retroperitoneal lymph node dissection and hepatic resection? J. Urol.184(3), 949–953 (2010).
   PubMed Web of Science ®Google Scholar
• Donohue JP, Leviovitch I, Foster RS, Baniel J, Tognoni P. Integration of surgery and systemic therapy: results and principles of integration. Semin. Urol. Oncol.16(2), 65–71 (1998).
   PubMedGoogle Scholar
• Sexton WJ, Wood CG, Kim R, Pisters LL. Repeat retroperitoneal lymph node dissection for metastatic testis cancer. J. Urol.169(4), 1353–1356 (2003).
   PubMed Web of Science ®Google Scholar
• McKiernan JM, Motzer RJ, Bajorin DF, Bacik J, Bosl GJ, Sheinfeld J. Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. Urology62(4), 732–736 (2003).
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Ohlmann C, Hegele A, Beyer J. Repeat retroperitoneal lymphadenectomy in advanced testicular cancer. Eur. Urol.47(1), 64–71 (2005).
   PubMed Web of Science ®Google Scholar
• Willis SF, Winkler M, Savage P, Seckl MJ, Christmas TJ. Repeat retroperitoneal lymph-node dissection after chemotherapy for metastatic testicular germ cell tumour. BJU Int.100(4), 809–812 (2007).
   PubMedGoogle Scholar
• Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP. Complications of post-chemotherapy retroperitoneal lymph node dissection. J. Urol.153(3 Pt 2), 976–980 (1995).
   PubMed Web of Science ®Google Scholar
• Williams SB, McDermott DW, Winston D et al. Morbidity of open retroperitoneal lymph node dissection for testicular cancer: contemporary perioperative data. BJU Int.105(7), 918–921 (2009).
   PubMedGoogle Scholar
• Subramanian VS, Nguyen CT, Stephenson AJ, Klein EA. Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer. Urol. Oncol.28(5), 504–509 (2010).
   PubMed Web of Science ®Google Scholar
• Evans JG, Spiess PE, Kamat AM et al. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J. Urol.176(4 Pt 1), 1463–1467 (2006).
   PubMedGoogle Scholar
• Donohue JP, Foster RS. Management of retroperitoneal recurrences. Seminoma and nonseminoma. Urol. Clin. North Am.21(4), 761–772 (1994).
   PubMed Web of Science ®Google Scholar
• Spiess PE, Tannir NM, Brown GA et al. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection. Urology70(6), 1173–1178 (2007).
   PubMedGoogle Scholar
• Svatek RS, Spiess PE, Sundi D et al. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer115(6), 1310–1317 (2009).
   PubMedGoogle Scholar
• Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP. Long-term outcome for patients with high volume retroperitoneal teratoma undergoing post-chemotherapy surgery. J. Urol.181(6), 2526–2532 (2009).
   PubMedGoogle Scholar
• Spiess PE, Kassouf W, Brown GA et al. Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J. Urol.177(4), 1330–1334; discussion 1334 (2007).
   PubMedGoogle Scholar
• Carver BS, Shayegan B, Serio A, Motzer RJ, Bosl GJ, Sheinfeld J. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J. Clin. Oncol.25(9), 1033–1037 (2007).
   PubMedGoogle Scholar
• Fizazi K, Tjulandin S, Salvioni R et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy – results from an international study group. J. Clin. Oncol.19(10), 2647–2657 (2001).
   PubMed Web of Science ®Google Scholar
• Fizazi K, Oldenburg J, Dunant A et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann. Oncol.19(2), 259–264 (2008).
   PubMed Web of Science ®Google Scholar
• Comiter CV, Kibel AS, Richie JP, Nucci MR, Renshaw AA. Prognostic features of teratomas with malignant transformation: a clinicopathological study of 21 cases. J. Urol.159(3), 859–863 (1998).
   PubMedGoogle Scholar
• Spiess PE, Pisters LL, Liu P et al. Malignant transformation of testicular teratoma: a chemoresistant phenotype. Urol. Oncol.26(6), 595–599 (2008).
   PubMedGoogle Scholar
• El Mesbahi O, Terrier-Lacombe MJ, Rebischung C, Theodore C, Vanel D, Fizazi K. Chemotherapy in patients with teratoma with malignant transformation. Eur. Urol.51(5), 1306–1311 (2007).
   PubMedGoogle Scholar
• Rick O, Bokemeyer C, Weinknecht S et al. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. J. Clin. Oncol.22(18), 3713–3719 (2004).
   PubMed Web of Science ®Google Scholar
• Eggener SE, Carver BS, Loeb S, Kondagunta GV, Bosl GJ, Sheinfeld J. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer109(3), 528–535 (2007).
   PubMed Web of Science ®Google Scholar
• Beck SD, Patel MI, Sheinfeld J. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors. J. Urol.171(1), 168–171 (2004).
   PubMedGoogle Scholar
• van der Gaast A, Hoekstra JW, Croles JJ, Splinter TA. Elevated serum tumor markers in patients with testicular cancer after induction chemotherapy due to a reservoir of markers in cystic differentiated mature teratoma. J. Urol.145(4), 829–831 (1991).
   PubMedGoogle Scholar